Moderna (MRNA) Tops Q1 EPS by 48c

Moderna (NASDAQ: MRNA) reported Q1 EPS of ($3.07), $0.48 better than the analyst estimate of ($3.55). Revenue for the quarter came in at $167 billion versus the consensus estimate of $94.28 million.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
• Goldman Sachs Starts Infratil New Zealand (IFT:NZ) at Buy